GSK Turkiye

What GSK Turkiye does

GSK Turkiye (Glaxosmithkline İlaçları San. Ve Tic. A.Ş.) is the Turkish operating subsidiary of UK-listed biopharmaceutical company GSK plc, present in Turkey since 1959 and headquartered in Sisli, Istanbul, employing approximately 600 staff. The company develops and distributes prescription medicines and vaccines across four therapeutic focus areas — Respiratory/Immunology and Inflammation, Oncology, HIV, and Infectious Diseases — serving Turkish patients via the country's pharmacy network and direct hospital supply. It is designated a priority country for GSK's clinical development investments, and operates within a global R&D machine that combines immunological science expertise with genetics, functional genomics, and AI/ML across the discovery-to-regulatory pipeline.

Core marketed assets include the RSV vaccine Arexvy (expanded in 2026 to adults aged 18–49 at risk), the IL-5 inhibitor biologic Exdensur (depemokimab) — approved by the European Commission in February 2026 as the first ultra-long-acting biologic for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps — oncology products Jemperli (dostarlimab, a PD-1 inhibitor) and Zejula (niraparib, a PARP inhibitor), the meningitis B vaccine Bexsero, and the oral carbapenem antibiotic Utebzi. The pipeline of 58 medicines and vaccines includes mocertatug rezetecan (B7-H4 targeting ADC for platinum-resistant ovarian cancer), bepirovirsen (an antisense oligonucleotide achieving a 19% functional cure rate in Phase 3 hepatitis B trials and filed for FDA priority review), camlipixant (a P2X3 receptor antagonist for chronic refractory cough), linerixibat (an IBAT inhibitor licensed to Alfasigma), and HS235 (acquired via 35Pharma for fat-selective weight loss with muscle preservation).

Revenue derives from prescription pharmaceutical sales across three streams: Specialty Medicines (asthma, cancer, HIV, and autoimmune diseases including lupus, accounting for over 40% of GSK group revenue), Vaccines (one of the broadest industry portfolios, with products from birth through adulthood), and General Medicines (asthma/COPD drugs and antibiotics). Distribution combines wholesale pharmacy supply with direct hospital relationships for specialty products, while healthcare-professional engagement is mediated through the dedicated GSK Pro portal. Pricing is regulated by the Turkish Pharmaceutical and Medical Device Institute (TITCK) and not publicly disclosed. The parent completed multiple high-value transactions during 2025–2026 — including Nuvalent ($10.6B), RAPT Therapeutics ($2.2B), and 35Pharma — alongside strategic partnerships such as the Hengrui Pharma overseas development agreement and adoption of the Microsoft Discovery agentic-AI platform.

Name

GSK Turkiye

Legal name

Glaxosmithkline İlaçları San. Ve Tic. A.Ş.

Website

https://tr.gsk.com

Company type

Private

Founded year

1959

Operating status

Operating

Headcount range

501–1,000 employees

Short description

GSK Turkiye is the Turkish subsidiary of UK-listed biopharmaceutical company GSK plc, developing and distributing specialty medicines, vaccines, and general medicines across respiratory, oncology, HIV, and infectious disease therapeutic areas through Turkey's pharmacy and hospital networks.

Ownership category

akta.pro rank

Headquarters

HQ city

Sisli

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. Specialty Medicines: Specialty medicines portfolio addressing asthma, cancer, HIV, and autoimmune diseases including lupus. Specialty medicines account for over 40% of GSK's total revenue.
2. Vaccines: One of the broadest vaccine portfolios in the industry, delivering millions of vaccine doses globally each year. Includes vaccines from birth through adulthood for infectious diseases.
3. General Medicines: General medicines including asthma and COPD medications, and antibiotics typically prescribed in primary care settings by family physicians or specialists.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

GSK Turkiye (Glaxosmithkline İlaçları San. Ve Tic. A.Ş.) is a biopharmaceutical company that discovers, develops, and commercializes vaccines and prescription medicines in Turkey. The company operates across four therapeutic areas — Respiratory/Immunology and Inflammation, Oncology, HIV, and Infectious Diseases — organized into three product groups: Specialty Medicines, Vaccines, and General Medicines. Products are distributed through pharmacies, hospitals, and healthcare facilities across Turkey, with dedicated engagement programs for healthcare professionals through the GSK Pro platform.

Product overview

GSK Turkiye operates as a biopharma company offering three main product categories: Specialty Medicines (covering asthma, cancer, HIV, and lupus), Vaccines (one of the broadest portfolios in the industry with products like Arexvy, Bexsero, and Shingrix), and General Medicines (including asthma/COPD and antibiotics). The company focuses on four therapeutic areas: Respiratory/Immunology and Inflammation, Oncology, HIV, and Infectious Diseases. Key products include Exdensur (depemokimab) for severe asthma and CRSwNP, Arexvy RSV vaccine, Bepirovirsen for hepatitis B, and various pipeline candidates including mocertatug rezetecan (ADC for ovarian cancer), camlipixant (for chronic cough), and linerixibat (licensed to Alfasigma). The R&D pipeline includes 58 medicines and vaccines in development.

Differentiator

Problem solved

Functional benefit

Brands

• GSK: Global biopharma company brand - GSK Turkiye operates under the GSK corporate brand for pharmaceuticals and vaccines

Products and services

• Exdensur (depemokimab) Ultra-long-acting IL-5 inhibitor biologic administered twice yearly for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps.
• Arexvy Respiratory Syncytial Virus (RSV) vaccine approved for adults aged 18 and older at increased risk for RSV-related lower respiratory tract disease.
• Bexsero Meningitis B vaccine administered in two doses, used in vaccination programs for young people.
• Jemperli (dostarlimab) PD-1 inhibitor used as companion diagnostic with Roche's VENTANA MMR RxDx Panel for mismatch repair deficient (dMMR) tumors in colorectal, endometrial, gastric, small intestine, and biliary cancers.
• Zejula (niraparib) PARP inhibitor for ovarian cancer, with Myriad Genetics' MyChoice CDx Test as companion diagnostic identifying HRD-positive patients.
• Mocertatug rezetecan (Mo-Rez) B7-H4 targeting ADC for platinum-resistant ovarian cancer and recurrent/advanced endometrial cancer, showing 62% ORR in Phase 1 BEHOLD-1 trial, advancing to five Phase 3 trials.
• Bepirovirsen Investigational antisense oligonucleotide for chronic hepatitis B achieving 19% functional cure rate in Phase 3 B-Well trials, filed for FDA approval with priority review.
• Camlipixant Drug candidate in development for chronic refractory cough, representing unmet need in the absence of approved targeted therapies.
• Ozureprubart Monoclonal antibody acquired through RAPT Therapeutics ($2.2B deal), targeting allergic and inflammatory immune responses for respiratory and immunology markets.
• Linerixibat Experimental IBAT inhibitor treatment for cholestatic pruritus in primary biliary cholingitis, licensed to Alfasigma for global development and commercialization (up to $690M deal).
• Utebzi (tebipenem pivoxil) First oral carbapenem antibiotic approved by FDA for complicated urinary tract infections including pyelonephritis, developed by GSK and Spero Therapeutics.

Quantifiable outcome

• 58 medicines and vaccines currently in development pipeline
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

Three partnerships are on record, tiered major and core.

• Hengrui PharmamajorStrategic or Co-development Partner · 25 March 2026Strategic collaboration between GSK and Hengrui Pharma for overseas business development transactions. This partnership is part of Hengrui's international expansion strategy, with GSK acting as a strategic partner in global markets.
• Toplum Gonulluleri Vakfi (TOG)coreStrategic or Co-development Partner · 6 February 2023Long-standing strategic partnership with Toplum Gonulluleri Vakfi (TOG) for social responsibility initiatives in Turkey. Collaboration includes multiple projects: Adiyaman Destek Merkezi (earthquake recovery support center), GSK ile Ataklar (environmental sustainability projects), Kirmizida Dur De! (child rights awareness), Saglikli Gençlik Hareketi (youth health literacy), and Baglanamam (anti-smoking awareness). Over 90 GSK volunteers have participated in various initiatives.
• Toplum Gonulluleri Vakfi (TOG) - Adiyaman Support CentercoreStrategic or Co-development Partner · 6 February 2023Earthquake recovery initiative following February 6, 2023 earthquakes. The Adiyaman Destek Merkezi has reached over 35,000 participants through 1,165 events, with support from 90 GSK volunteers. The center provides psycho-social support, educational activities, and youth empowerment programs for earthquake-affected communities.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Novartis Turkey: Turkish affiliate of Novartis, competing in respiratory, oncology, and specialty medicines. Operates with a comparable field-sales-plus-market-access model targeting Turkish healthcare professionals and hospital accounts.
• Pfizer Turkey: Turkish subsidiary of Pfizer, a top global biopharma with overlapping respiratory, oncology, and infectious disease portfolios. Directly competes with GSK Turkiye for physician share-of-voice and tender wins in the same therapeutic areas.
• Roche Turkey: Turkish subsidiary of Roche, a direct oncology and respiratory competitor. Even co-markets companion diagnostics (e.g., VENTANA MMR RxDx) with GSK's Jemperli, making it both a competitor and an intertwined commercial partner.
• Sanofi Turkey: Turkish operations of Sanofi, with overlapping specialty medicines, vaccines, and general medicines portfolios. Competes directly with GSK Turkiye across respiratory, immunology, and vaccine categories in Turkey.
• MSD (Merck) Turkey: Turkish subsidiary of Merck & Co., a leading oncology and vaccines competitor. Overlaps with GSK in oncology (PD-1 inhibitor Keytruda versus Jemperli) and vaccines, with similar enterprise sales motion toward Turkish healthcare providers.
• AstraZeneca Turkey: Turkish affiliate of AstraZeneca, a major competitor in oncology (PARP, ADC) and respiratory. Directly competes with GSK's Zejula, Jemperli, and respiratory portfolio for share in Turkish hospital channels.
• Johnson & Johnson Innovative Medicine Turkey: Turkish pharmaceutical operations of J&J, competing in immunology, oncology, and infectious diseases. Comparable scale and field-sales model to GSK Turkiye, with overlapping specialty portfolios.
• AbbVie Turkey: Turkish subsidiary of AbbVie, with immunology and oncology overlap (Humira/Skyrizi/Rinvoq competing with GSK's immunology assets). Competes for the same physician specialties and reimbursement slots in Turkey.
• Bayer Turkey: Turkish pharmaceutical operations of Bayer, with overlapping cardiovascular, women's health, and specialty portfolios. Competes in the same general/specialty medicine categories through Turkish pharmacy and hospital channels.

Regional players

• Takeda Turkey: Turkish subsidiary of Takeda, with focus on rare diseases, oncology, and specialty medicines. Competes with GSK Turkiye in specialty immunology and oncology, though with a distinct rare-disease tilt.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/GSKTurkiye
• YouTubeyoutube.com/c/GSKTR
• Facebookfacebook.com/GSKTurkiye

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GSK Turkiye